Genetic-based testing and treatment for breast cancer

Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer.

Genomic testing is changing the way breast cancer is diagnosed and treated. By examining a woman’s genes to look for specific mutations or biomarkers, treatment can be personalised to the tumour cell’s biology and a woman’s genetics.

‘A personalised approach increases the precision and success of breast cancer treatment,’ said Gregory Tsongalis, PhD, director of Molecular Pathology at Norris Cotton Cancer Center and lead author of the paper. ‘Molecular profiling exposes a tumour’s Achilles’ heel. We can see what messages the tumour cells are receiving and sending. It is a biological intelligence gathering mission in an attempt to interrupt the disease.

According to Tsongalis large scale genetic testing of breast cancer is not yet part of routine clinical care as it is with lung and colon cancers, even though he and his team run a genetics laboratory for routine cancer care. Genetic testing according to Tsongalis is a powerful weapon in the diagnosis and treatment of breast cancer.

With results from the genetic testing of a tumour cell’s biology, clinicians categorise breast cancer in ways that allow them to select the most effective treatments. Based on genetic biomarkers, there are three categories of breast cancer:
1. ER-positive breast cancer needs hormones, such as oestrogen to grow. Oestrogen fuels cancer cell growth, stops cancer cells from dying, and helps the cells lay down roots to maintain blood supply for tumours. ER-positive cancers are less aggressive and often treated with drugs that are selective estrogen receptor modulators (SERM).
2. HER2 –positive breast cancer cells contain large amounts of protein that help them grow and multiply. Medications turn off the production of protein to stop tumour growth and kill cancer cells.
3. Triple negative (ER-negative/PR-negative/HER2-negative) breast cancer is the most aggressive type and has the poorest clinical outcome. There is no approved personalised therapy for triple negative, but research has identified six subtypes of tumours. This is the first step in identifying biomarkers that can lead to the development of personalised treatments.

‘Genomic testing of breast cancer has expanded our understanding of the disease process and has proven more effective than traditional laboratory tests,’ said Tsongalis. ‘At NCCC all of our breast cancer patients are tested for abnormal copies of the HER2 gene using specially designed DNA probes. New biomarkers and the reclassification of cancers based on these biomarkers has led to the development of new, effective treatments that can be personalised to an individual breast cancer patient.’ Norris Cotton Cancer Center